Compare AbbVie Inc (ABBV) vs American States Water Company (AWR) Price & Performance

AbbVie (ABBV) trades at $249.94, up 0.82% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $3.87. Revenue growth is robust, projected at $64.4B for 2026, driven by immunology drugs Skyrizi and Rinvoq offsetting Humira declines. The company maintains a solid dividend, with a recent $1.73 payout announced for H2-2026.

The outlook for ABBV is positive, supported by earnings momentum and a diversified pipeline, though high valuation ratios and patent cliffs in the 2030s present risks. Institutional ownership is growing, reflecting confidence in the company's strategic direction. Investors should weigh the strong growth prospects against the elevated P/E of 70.27 and significant long-term debt of $60.34B.

AWR trades at $87.95, up 1.59% on the day, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $1.09 versus $0.915 expected, driven by water rate increases and revenue growth. Recent news highlights its 71-year dividend growth streak and an 8.2% dividend hike announced in July 2026. Financials show solid profitability with a 20.52% net income margin and ROE of 13.62%, though valuation ratios like P/E of 23.92 are above sector averages.

Outlook is mixed: strong dividend history and earnings growth support income investors, but elevated valuation and mixed analyst consensus (20% buy, 50% hold, 30% sell) suggest limited near-term upside. Key risks include regulatory dependence on rate approvals and potential overvaluation relative to peers.